Nonalcoholic steatohepatitis (NASH)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: CHS-131 in Nonalcoholic steatohepatitis (NASH)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
05-07-2020 First Quarter 2020 Financial Results
05-09-2019 Initiate clinical phase program in NASH - Corporate Highlights and Q1 2019 Results
Elafibranor - Genfit
Ocalvia - Intercept Pharmaceuticals
VK2809 - Viking Therapeutics
~20 percent of people with NAFLD have NASH
Between 30 and 40 percent of adults in the United States have NAFLD.
~ 3 to 12 percent of adults in the United States have NASH
MECHANISM OF ACTION / RATIONALE
CHS-131, a first-in-class, non-immunosuppressive, highly-selective PPARγ agonist that crosses the blood-brain-barrier, has potent anti-inflammatory activity and is clinically effective in EAE.
Updated by HC
#CHRS, #CHS-131, # Nonalcoholic_steatohepatitis, #NASH
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post